Current SINOVAC Directors Elected Properly at the 2018 Annual General Meeting The Company's Rights Agreement is Valid under Antigua LawDecember 9, 2021 -- BEIJING--SINOVAC Biotech Ltd. (NASDAQ: SV

Instituto Butantan, in partnership with Sinovac Biotech, is pleased to announce CoronaVac® Symposium, an international online event that aims to promote and discuss the latest results of the efficacy

Beijing，November 18, 2021, the 2nd International Conference on the Latest Researches and Experience Sharing on SINOVAC's COVID-19 Vaccine hosted by SINOVAC Biotech Ltd (SIONVAC). was held successf

Yangon, Myanmar- 8 November, 2021Sea Lion Group is pleased to announce a collaboration with Sinovac Biotech Ltd. (SINOVAC) to facilitate the c

The Egyptian delegation led by H.E. Ambassador to China Dr. Mohamed Elbadri visited the production base of Sinovac Life Sciences in Daxing, Beijing on 21 October 2021, accompanied by Chairman Weidong

· Doses will be available through SGX-Catalist listed Livingstone Health group at 17 clinics islandwide· Inactivated viral vaccines offer an alternative option for those unable to take up vaccines ava

Study findings demonstrate that a booster dose of inactivated COVID-19 vaccine produces a highly sifted, humoral immune response via a sustained evolution of antibodies, able to effectively neutralize

BEIJING, China, Sep 9, 2021 – SINOVAC Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that Coron

CoronaVac® generates good immune memory after second doseThird dose of vaccine significantly increased neutralizing antibody levels in adults and elderly populationFindings indicate a third dose of Co

CoronaVac® generates good immune memory after the second doseThird dose of CoronaVac® induces strong immune response No serious adverse reactions reportedAdverse reactions reported within 28 day after

BEIJING, China, July 19, 2021 -- SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced CoronaV

SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced it received a drug registration approval

SINOVAC Biotech Ltd. ("SINOVAC") recently noticed a Portuguese-language press release with a statement that does not conform to the facts. This fraudulent statement ("Fraudulent Stateme

BEIJING, China, July 12, 2021 -- SINOVAC Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that it

The Lancet Infectious Diseases Published Data from Sinovac’s Phase I/II Study, World’s First Published Study on Clinical Trial Results of a COVID-19 Vaccine in Healthy Children and Adolescents Aged 3

BEIJING – June 12, 2021 – SINOVAC Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that Inlive®, an innovative, inact

BEIJING--(BUSINESS WIRE)--SINOVAC Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that CoronaVac®, an innovative, in

BEIJING--Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2020 annual report on Form 20-F with the U.S. Securit